Successful Treatment of Behcet Disease with Pentoxifylline
Authors: Kozo Yasui
Journal: Annals of Internal Medicine (1996)

Brief Reports15 May 1996Successful Treatment of Behcet Disease with PentoxifyllineKozo Yasui, MD, Kouichi Ohta, MD, Masakazu Kobayashi, MD, Toru Aizawa, MD, and Atsushi Komiyama, MDKozo Yasui, MD, Kouichi Ohta, MD, Masakazu Kobayashi, MD, Toru Aizawa, MD, and Atsushi Komiyama, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-10-199605150-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Behcet disease is a chronic condition that is common in Japan and the countries on the Mediterranean Sea. Its cause is still unknown, but its occurrence is strongly associated with HLA-B51 antigen. Neutrophil motility and superoxide production are characteristically increased in patients with Behcet disease.Pentoxifylline is a membrane fluidizer that modulates receptor-mediated cellular functions [1]. It also modulates neutrophil motility, suppresses production of superoxide anion (O2−), and reduces neutrophil-induced tissue damage [1, 2].We examined the effect of pentoxifylline in controlling Behcet disease. We administered 600 mg of pentoxifylline per day, in two doses, to three male patients and ...References1. Hill HR, Augustine NH, Newton JA, Shigeoka AO, Morris E, Sacchi F. Correction of a developmental defect in neutrophil activation and movement. Am J Pathol. 1987; 128:307-14. Google Scholar2. Buescher ES, Mcllheran SM, Banks SM, Vadhan-Raj S. Alteration of the functional effects of granulocyte-macrophage colony-stimulating factor on polymorphonuclear leukocytes by membrane-fluidizing agents. Infect Immun. 1990; 58:3002-8. Google Scholar3. Nelson RD, Quie PG, Simmons RL. Chemotaxis under agarose: a new and simple method for measuring chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes. J Immunol. 1975; 115:1650-6. Google Scholar4. Cohen HJ, Chovaniec ME. Superoxide generation by digitonin-stimulated guinea pig granulocytes. A basis for a continuous assay for monitoring superoxide production and for the study of the activation of the generating system. J Clin Invest. 1978; 61:1081-7. Google Scholar5. Craddock PR, Hammerschmidt DE, Moldow CF, Yamada O, Jacob HS. Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination, microvascular occlusion, and endothelial damage. Semin Hematol. 1979; 16:140-7. Google Scholar6. Yasui K, Komiyama A, Molski TF, Sha'afi RI. Pentoxifylline and CD14 antibody additively inhibit priming of polymorphonuclear leukocytes for enhanced release of superoxide by lipopolysaccharide: possible mechanism of these actions. Infect Immun. 1994; 62:922-7. Google Scholar7. Matsumura N, Mizushima Y. Leucocyte movement and colchicine treatment in Behcet's disease [Letter]. Lancet. 1975; 2:813. Google Scholar8. Kitagawa S, Takaku F. Effect of microtubule-disrupting agents on superoxide production in human polymorphonuclear leukocytes. Biochim Biophys Acta. 1982; 719:589-98. Google Scholar9. Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. A double blind study of colchicine in Behcet's disease. Haematologica. 1980; 65:399-402. Google Scholar10. Yazici H, Barnes CG. Practical treatment recommendations for pharmacotherapy of Behcet's syndrome. Drugs. 1991; 42:796-804. Google Scholar11. Lingenfelser T, Duerk H, Stevens A, Grossmann T, Knorr M, Saal JG. Generalized myositis in Behcet disease: treatment with cyclosporine. Ann Intern Med. 1992; 116:651-3. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAdamantiades–Behçet's DiseaseGenetics and immunodysfunction underlying Behçet's disease and immunomodulant treatment approachesThe role of classical and alternative macrophages in the immunopathogenesis of herpes simplex virus-induced inflammation in a mouse modelTraitement de la maladie de BehçetApproaches to immunosuppression in Behçet's diseaseNew Evidence-Based Treatment Approach in Behçet's DiseaseSkin and Bone DisordersSystemic Therapy With Conventional and Novel Immunomodulatory Agents for Ocular Inflammatory DiseaseReduced erythrocyte deformability in active and untreated Behçet's disease patientsMedical Management of Behçet's SyndromeMaladie de BehçetMaladie de Behçet : les nouvelles thérapeutiquesBehçet's disease – a contemporary reviewMaladie de BehçetEnfermedad de BehçetTraitements actuels et perspectives thérapeutiques dans la maladie de BehçetInfliximab as an Alternative Treatment for Behçet Disease When Other Therapies FailAdamantiades–Behçet's DiseasePentoxifylline Inhibits Vγ9/Vδ2 T Lymphocyte Activation of Patients with Active Behçet's Disease in VitroRole of red blood cell flow behavior in hemodynamics and hemostasisMucocutaneous Lesions of Behçet's DiseaseBeh??et DiseasePentoxifylline : l'anti-TNF du pauvre ?Skin and Bone DisordersInvestigations and management of gastrointestinal and hepatic manifestations of systemic lupus erythematosusCurrent Concepts in the Etiology and Treatment of Behçet DiseaseBehçet's disease: Current therapeutic perspectivesAssociation of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's diseaseOxpentifylline is not effective for symptomatic oral lichen planusBehçet's DiseaseClinical pathologic conferenceMapping the HLA association in Behçet's disease: A role for tumor necrosis factor polymorphisms?Adamantiades-Behçet's diseaseComplex aphthosis and Behçet's diseaseMiscellaneous treatments, I: sulfasalazine and pentoxifylline: unapproved uses, dosages, or indicationsTreatment with pentoxifylline in Behcet's diseaseAphthen und Morbus Adamantiades-BehçetTreatment of Behçet's disease—An updateAnti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case reportNew clinical applications of xanthine derivatives: Modulatory actions on leukocyte survival and functionCombination therapy including pentoxifylline for entero-Behcet's disease.Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trialPentoxifylline and alcoholic hepatitisBehçet's diseaseNovel approaches to Behçet's diseaseOral disorders: unapproved treatments or indications11The opinions expressed herein are solely those of the investigators and do not necessarily reflect the opinions of the institutions with which they are associated.Cerebral Venous Thrombosis and the G20210A Mutation of Factor IIAdamantiades-Behçet's DiseasePentoxifilina en el tratamiento de la aftosis orogenital y del síndrome de BehçetDISORDERS THAT MIMIC CENTRAL NERVOUS SYSTEM INFECTIONSBehçet's DiseaseAcute pancreatitis and pericardial effusion in Behçet's diseaseEnhancement of Endothelial Cell E-Selectin Expression by Sera from Patients with Active Behçet's Disease: Moderate Correlation with Anti-endothelial Cell Antibodies and Serum Myeloperoxidase LevelsContemporary evaluation and management of aphthous stomatitisBehçet's disease in childrenReplyDERMATOLOGY THERAPY UPDATERegulation of adenylyl cyclase activity in human peripheral blood mononuclear cells: effects of protein kinase inhibitors and of a calcium ionophorePrevention of nickel-induced allergic contact reactions with pentoxifyllineRecurrent Aphthous StomatitisPentoxifylline Potentiates In Vitro Lymphocyte Suppression by Glucocorticoids and Immunosuppressive DrugsBehçet's Disease versus Behçet's Syndrome with Some Criteria for Systemic Lupus ErythematosusBehçet's disease: an immune-mediated vasculitis involving vessels of all sizesMouth and Genital Ulcers With Inflamed Cartilage (MAGIC Syndrome): A Case Report and Literature ReviewPentoxifylline Use for Behçet's DiseaseBehçet's Syndrome: From Aetiology to Treatment 15 May 1996Volume 124, Issue 10Page: 891-893KeywordsAntigensAttentionC-reactive proteinsChemotaxisColchicineEye diseasesNeutrophilsUlcersUveitisVisual acuity Issue Published: 15 May 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...